Could a new drug finally silence chronic cough?
NCT ID NCT04765722
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether mepolizumab, a drug already used for asthma, can reduce coughing in people with chronic cough and eosinophilic airway disease. 46 adults received either the drug or a placebo over 12 weeks. The main goal was to see if cough frequency decreased, measured by a special monitor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mepolizumab (Nucala)
- What this could lead to
- If successful, this could point toward a new treatment option for chronic cough in people with certain airway conditions.
- What could go wrong
- This is a small, early proof-of-concept study with only 46 participants, so results may not apply to everyone. The drug may not significantly reduce cough frequency.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McMaster University
Hamilton, Ontario, L8S 4L8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?